Condition: Breast Cancer · Sponsor: Mridula George, MD
This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess the benefits of concurrent use of these treatments in a specific participant population, focusing on their safety and tolerability. The hypothesis is that the combination therapy will be well-tolerated, providing valuable insights into its effectiveness for future clinical applications.
This description comes directly from the study's public registry record.
Mridula A George, MD · 732-235-9081 · mridula@cinj.rutgers.edu
Mridula A George, MD · Mridula · mridula@cinj.rutgers.edu
Always discuss trial participation with your own doctor first.
| RWJBarnabas Health Clara Maas Medical Center | Belleville, New Jersey, United States | Recruiting |
| Cooperman Barnabas Medical Center | Livingston, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital Somerset | Somerville, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06139107